
Cambridge’s TRIMTECH Therapeutics brings Seed round to €41 million for neurodegenerative disease work - EU-Startups
TRIMTECH Therapeutics is focused on developing innovative treatments for neurodegenerative diseases. The company aims to address significant unmet medical needs in this area, making it a notable player in the health sector. The recent funding round will support their research and development efforts.
Cambridge’s TRIMTECH Therapeutics brings Seed round to €41 million for neurodegenerative disease work EU-Startups
| Jun 23, 2026 | Astral Systems | $27.6M | Series A | United Kingdom |
| Jun 22, 2026 | Isometric | $36.4M | — | United Kingdom |
| Jun 18, 2026 | NHS AI agent startup | $12K | — | United Kingdom |
| Jun 18, 2026 | Space Forge | $12K | Grant | United Kingdom |